Editorial Comment for URL-D-23-01604R1: Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment

Oxybutynin, first introduced in 1975, has long been the pharmacologic mainstay of overactive bladder (OAB) treatment. It has demonstrated clinical success in addressing bothersome OAB and urge urinary incontinence symptoms and maintains a strong clinical foothold in managing neurogenic bladder in both pediatric and adult populations. However, a growing body of evidence as outlined in this review, has demonstrated that both short and long-term use may result in adverse cognitive outcomes, including impaired memory and increased dementia risk.
Source: Urology - Category: Urology & Nephrology Authors: Tags: Editorial Comment Source Type: research